CP and hepatocellular carcinoma: Currently, the combination of atezolizumab and bevacizumab is a standard of care option in the first-line setting for eligible patients with advanced HCC based on the IMbrave150 clinical trial, which demonstrated survival benefit compared to sorafenib.6 However, this trial was limited to patients with CP class A liver function, with 72% having CP-A5 and 28% having CP-A6 liver function.